DURATION

Dual antiplatelet Use for extended period taRgeted to AcuTe Ischemic stroke with presumed atherosclerotic OrigiN (DURATION)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004407

Enrollment

4748

Registered

2019-10-31

Start date

2020-07-07

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : intervention: 1-year duration of dual ntiplatelet with aspirin and clopidogrel, control: 3-month duration of dual antiplatelet with aspirin and clopidogrel, then clopidogrel (or aspirin) monoth

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with acute ischemic stroke or transient ischemic attack with positive DWI lesions within 7 days of onset, 2) patients starting treatment with clopidogrel-aspirin within 7 days of onset, 3) patients with presumed large artery atherosclerotic origin according to the TOAST classification, 4) patients signed informed consent

Exclusion criteria

Exclusion criteria: 1) Ineligible and unwilling to maintain over 3-months DAPT based on the physician’s discretion, 2) Eligible and willing to maintain over 3-months DAPT based on the physician’s discretion

Design outcomes

Primary

Measure	Time frame
a composite of stroke, myocardial infarction, or all-causea mortality	—

Secondary

Measure	Time frame
1-year all types of stroke (either ischemic or hemorrhagic stroke);1-year ischemic stroke;1-year hemorrhagic stroke;1-year all-cause mortality;1-year major bleeding	—

Countries

Korea, Republic of

Contacts

Public ContactSeung Lee

Seoul National University Bundang Hospital

butteri1004@gmail.com+82-31-787-8307

Outcome results